Rituximab tops other disease-modifying tx options in MS

January 9, 2018

(HealthDay)—Rituximab has better efficacy and lower discontinuation rates than other disease-modifying treatment (DMT) choices for newly diagnosed relapsing-remitting multiple sclerosis (RRMS), according to a study published online Jan. 8 in JAMA Neurology.

Mathias Granqvist, M.D., from the Karolinska Institutet in Stockholm, and colleagues conducted a using prospectively collected data for patients in Sweden with newly diagnosed RRMS. The effectiveness and drug discontinuation rates of rituximab were compared with those of injectable DMTs, , fingolimod, and natalizumab.

Of the 494 patients, 43.5 percent received an injectable DMT, 17.4 percent dimethyl fumarate, 3.4 percent fingolimod, 10.1 percent natalizumab, 24.3 percent rituximab, and 1.2 percent other DMT. The researchers found that there were pronounced regional preferences, with 81 and 18 percent of patients in Västerbotten and Stockholm, respectively, receiving rituximab. The annual discontinuation rates were 0.03, 0.53, 0.32, 0.38, and 0.29 for rituximab, injectable DMTs, dimethyl fumarate, fingolimod, and natalizumab, respectively. The main reason for discontinuation of injectable DMTs, dimethyl fumarate, and fingolimod was continued disease activity; the main reason for discontinuation of natalizumab was positive John Cunningham virus serology results. Compared with injectable DMTs and dimethyl fumarate, the rates of clinical relapse and/or neuroradiologic disease activity were significantly lower for rituximab, with a tendency for lower relapse rates relative to and .

"Collectively, our findings suggest that rituximab performs better than other commonly used DMTs in patients with newly diagnosed RRMS," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Biogen, which manufactures .

Explore further: Rituximab effective for lupus-associated cytopenia

More information: Abstract/Full Text

Related Stories

Rituximab effective for lupus-associated cytopenia

December 27, 2017
(HealthDay)—Rituximab treatment seems effective for systemic lupus erythematosus (SLE)-associated immune cytopenias, with an overall initial response rate of 86 percent, according to a study published online Dec. 16 in ...

PFS up with obinutuzumab-based Tx in follicular lymphoma

October 5, 2017
(HealthDay)—For patients with follicular lymphoma, obinutuzumab-based immunochemotherapy is associated with longer progression-free survival than rituximab-based therapy, according to a study published online Oct. 4 in ...

Natalizumab shows promise for teens with multiple sclerosis

February 22, 2013
(HealthDay)—Natalizumab may be safe in pediatric multiple sclerosis (MS) patients with highly active disease, according to a small study published online Feb. 18 in JAMA Neurology.

Adding rituximab to chemo ups event-free survival in ALL

September 20, 2016
(HealthDay)—For young adults with acute lymphoblastic leukemia (ALL), adding rituximab to chemotherapy is associated with increased event-free survival, according to a study published in the Sept. 15 issue of the New England ...

Dimethyl fumarate linked to development of PML

April 9, 2015
(HealthDay)—An active ingredient in some psoriasis and multiple sclerosis medications, dimethyl fumarate, has been linked to two cases of progressive multifocal leukoencephalopathy (PML), according to two letters published ...

Tocilizumab treats rheumatoid arthritis after non-TNFi failure

March 30, 2016
(HealthDay)—For patients with rheumatoid arthritis (RA) and a first non-tumor necrosis factor inhibitor (TNFi) failure, treatment with tocilizumab seems more efficacious than abatacept or rituximab, according to a study ...

Recommended for you

Study finds alcohol dampens brain waves associated with decision-making but not motor control

March 15, 2018
We all know that alcohol impairs our judgement, alertness and performance on tasks requiring attention, but the mechanism behind booze's effect on cognition still isn't well-understood. Now, a new study led by psychologists ...

Research reveals brain mechanism involved in language learning

March 15, 2018
Learning a new language may be more of a science than an art, a University of Sussex study finds.

New research sheds light on underlying cause of brain injury in stroke

March 15, 2018
New research shows how the novel drug QNZ-46 can help to lessen the effects of excess release of glutamate in the brain – the main cause of brain injury in stroke.

New tissue technique gives stunning 3-D insights into the human brain

March 15, 2018
Imperial researchers have helped develop a breakthrough imaging technique which reveals the ultra-fine structure of the brain in unprecedented detail.

Cell therapy could improve brain function for Alzheimer's disease

March 15, 2018
Like a great orchestra, your brain relies on the perfect coordination of many elements to function properly. And if one of those elements is out of sync, it affects the entire ensemble. In Alzheimer's disease, for instance, ...

Altering songbird brain provides insight into human behavior

March 15, 2018
Songbirds are providing insight into how a specific set of neurons may guide the learning of vocal behaviors in humans.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.